Public Release: 

NIH awards will support development of therapeutic alternatives to traditional antibiotics

NIH/National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $5 million in funding for 24 research projects seeking to develop non-traditional therapeutics for bacterial infections to help address the growing health threat of antibiotic resistance. Advancing new therapeutic options to combat drug-resistant bacteria is a key goal of the President's National Action Plan for Combating Antibiotic-Resistant Bacteria.

"The discovery, development and deployment of antibiotics have transformed medicine; however, microbes continually evolve and become resistant to these lifesaving drugs," said NIAID Director Anthony S. Fauci, M.D. "New strategies are desperately needed to treat patients with antibiotic-resistant infections that often are deadly. These new NIAID grants will provide funding to researchers developing unique, non-traditional therapies that could complement or even replace currently available antibiotics that are losing effectiveness."

Increasing resistance to antibiotics coupled with the slow pace of new antibiotic development threatens to erode the past 70 years of progress in fighting life-threatening bacterial infections. The overuse and abuse of antibiotics drives this issue and, as a consequence, bacteria adapt to antibiotics designed to destroy them, making the drugs less effective and allowing antibiotic-resistant strains to survive and multiply.

A non-traditional therapeutic is an antibacterial treatment that works differently than traditional antibiotics, which typically target one or more essential pathways, such as those involved in cell-wall and protein synthesis, to directly kill or inhibit the growth of many types of bacteria. One non-traditional approach, called therapeutic bacteria, uses good bacteria found in or added to the human microbiome to target or control the growth of harmful bacteria. Another alternative approach is bacteriophage or phage therapy, which uses viruses that only affect bacteria to reduce or eliminate those bacteria in humans. Other examples of non-traditional approaches include adding decoy targets to prevent bacterial pathogens from producing disease, enhancing human immune responses to pathogens, and developing drugs that incapacitate the pathogen's ability to adapt and compete. For more information on NIAID's research in this area, please see the recent report NIAID's Antibacterial Resistance Program: Current Status and Future Directions.

The 24 phased innovation awards were made to 18 academic institutions and three industrial organizations. The awards provide support for two years with the possibility of three additional years of funding for the most accomplished projects. The recipients are as follows:

Avidbiotics Corporation
Project Title: Development of Modified R-Type Bacteriocins to Specifically Target Clostridium Difficile and Prevent Relapse of Clostridium Difficile Infections
Principal Investigator: Gregory Govoni
Grant: 1 R21AI121692-01

Baylor College of Medicine
Project Title: Defined Microbial Communities for the Treatment of Recurrent Clostridium Difficile Infection
Principal Investigator: Robert Britton
Grant: 1 R21AI121522-01

Project Title: Bacteriophage to Treat Urinary Tract Infections (UTIs) Caused by Multidrug-Resistant Pseudomonas Aeruginosa
Principal Investigator: Robert Ramig
Grant: 1 R21AI121545-01

Brigham and Women's Hospital
Project Title: Development of the RNA Molecule-Enriched, Cell Type-Specific Exosomes
Principal Investigator: Yang Jin
Grant: 1 R21AI121644-01

Project Title: Development of HAMLET as an Adjuvant for the Treatment of Drug-Resistant Staphylococcus Aureus Infections
Principal Investigators: Katie Edwards, Anders Hakansson
Grant: 1 R21AI121614-01

Emory University
Project Title: Polymeric Agents for the Treatment of Clostridium Difficile Infections
Principal Investigators: Shonna McBride, Samuel Gellman
Grant: 1 R21AI121684-01

Indiana University--Purdue University at Indianapolis
Project Title: Development of Anti-Virulence Drugs by Targeting the SaeRS Two-Component System of Staphylococcus Aureus
Principal Investigator: Taeok Bae
Grant: 1 R21AI121664-01

Massachusetts General Hospital
Project Title: Synergistic Photodynamic Therapy for Catheter-Associated Urinary Tract Infections (UTIs)
Principal Investigator: Michael Hamblin
Grant: 1 R21AI121700-01

Massachusetts Institute of Technology
Project Title: Engineering "Phagebody" Antimicrobials for Carbapenem-Resistant Enterobacteriaceae
Principal Investigator: Timothy Lu
Grant: 1 R21AI121669-01

Medical College of Wisconsin
Project Title: Bacteriophage to Prevent Infection by Antibiotic-Resistant Enterococci
Principal Investigator: Christopher Kristich
Grant: 1 R21AI121552-01

Queen's University at Kingston
Project Title: Microbes that Matter: Defining Optimal Formulations for Microbial Ecosystem Therapeutics
Principal Investigators: Elaine Petrof, Emma Allen-Vercoe
Grant: 1 R21AI121575-01

The State University of New York at Stony Brook
Project Title: Small Molecule Inhibition of Pilus Biogenesis by Pathogenic Bacteria
Principal Investigator: David Thanassi
Grant: 1 R21AI121639-01

Synthetic Genomics Vaccines, Inc.
Project Title: Towards the Development of Engineered Phage Therapeutics Against Multidrug-Resistant Pathogens
Principal Investigator: Bolyn Hubby
Grant: 1 R21AI121531-01

Texas A&M Agrilife Research
Project Title: Development of Therapeutic Bacteriophages against Carbapenemase-Resistant Klebsiella Pneumoniae
Principal Investigators: Jason Gill, Thomas Walsh
Grant: 1 R21AI121689-01

University of Arizona
Project Title: A Safe, Targeted, Designer Probiotic to Prevent or Treat Clostridium Difficile Infection
Principal Investigator: Gayatri Vedantam
Grant: 1 R21AI121590-01

University of California, San Diego
Project Title: Nanoparticle Decoys for Treating Infections with Enterotoxin-Producing Pathogens
Principal Investigators: Lars Eckmann, Liangfang Zhang
Grant: 1 R21AI121571-01

University of Colorado
Project Title: Development of Novel Resistance-Modifying Agents for Methicillin-Resistant Staphylococcus Aureus (MRSA)
Principal Investigator: Xiang Wang
Grant: 1 R21AI121581-01

Project Title: A Novel Screen for Antibacterials that Are Non-Toxic to Mammals
Principal Investigators: Corella Detweiler, Xiang Wang
Grant: 1 R21AI121365-01

University of Texas, Austin
Project Title: Phage Depolymerases as Antibiotics
Principal Investigators: James Bull, Ian Molineux
Grant: 1 R21AI121685-01

University of Texas Health Science Center
Project Title: Targeting Cell Membrane Adaptation in Multidrug-Resistant Enterococcus Faecium
Principal Investigator: Cesar Arias
Grant: 1 R21AI121519-01

University of Texas Medical Branch
Project Title: Therapeutic Potential of Cystatin 9 Treatment to Fight Bacterial Pneumonia
Principal Investigator: Tonyia Eaves-Pyles
Grant: 1 R21AI121604-01

University of Sydney
Project Title: Harnessing Bacteriophages as Natural Predators to Combat the Superbugs: A Pulmonary Drug Delivery Approach
Principal Investigator: Kim Chan
Grant: 1 R21AI121627-01

University of Wisconsin-Madison
Project Title: Microbial-Ecology Guided Discovery of Non-Traditional Therapeutics that Limit Resistance
Principal Investigator: Jason Kwan
Grant: 1 R21AI121704-01

Project Title: A Biotherapeutic CRISPR-Delivery Platform to Eradicate Clostridium Difficile
Principal Investigator: Jan-Peter van Pijkeren
Grant: 1 R21AI121662-01


NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health®

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.